VivaVision Biotech
PrivateLast Round
Series D+
Nov 1, 2025
Est. Valuation
$257.37M
Total Funding Raised
$131.09M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
VivaVision Biotech operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series D+ round in November 2025.
VivaVision Biotech is a clinical-stage pharmaceutical company that develops best-in-class and first-in-class therapies for ocular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VivaVision Biotech Comparables
Compare VivaVision Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BRIM Biotechnology, Inc. | 81% | |
| Arctic Vision | 80% | |
| Ocumension Therapeutics | 80% |
For institutional investors. Book with your work email.
VivaVision Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D+ | Nov 1, 2025 | ||||
| Grant | Jan 5, 2024 | ||||
| Series D Extension | May 6, 2023 | ||||
| Series D Extension | Apr 1, 2023 | ||||
| Series D | Apr 19, 2021 | ||||
Series C | Nov 1, 2019 |
For institutional investors. Book with your work email.
VivaVision Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| V-Capital | Series D Extension |
| Lapam Capital | Series D, Series B |
| Cenova Capital | Series D |
| Viva Biotech | Series B, Series A Extension, Series D |
| Innovation and Technology Commission | Grant |
| JMCR Partners | Series D, Series C |
| Shenzhen GTJA Investment Group | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 133% MoM.
- Mar 3, 2026
Monthly visitors increased 54% MoM.
For institutional investors. Book with your work email.
VivaVision Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VivaVision Biotech's valuation, stock price, and market status.
Is VivaVision Biotech a public or private company?
VivaVision Biotech is a private company.
What is the current stock price of VivaVision Biotech?
VivaVision Biotech is a private company, so its shares have no public market price. Caplight tracks VivaVision Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VivaVision Biotech worth (valuation)?
VivaVision Biotech's valuation is estimated at $257.4M based on funding round data.
Can I buy VivaVision Biotech stock?
VivaVision Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VivaVision Biotech's last funding round?
VivaVision Biotech's most recent funding round was Series D+ on November 1, 2025.
Who are the main investors in VivaVision Biotech?
Key investors in VivaVision Biotech include V-Capital, Lapam Capital, Cenova Capital, HongShan Capital Group (HSG).
Will VivaVision Biotech IPO soon?
No public IPO plans have been announced for VivaVision Biotech.
How can I track VivaVision Biotech secondary market activity?
Caplight tracks bids, offers, and trades in VivaVision Biotech's shares on secondary markets.